Robert Orenstein

4.4k total citations · 2 hit papers
100 papers, 3.0k citations indexed

About

Robert Orenstein is a scholar working on Infectious Diseases, Epidemiology and Critical Care and Intensive Care Medicine. According to data from OpenAlex, Robert Orenstein has authored 100 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Infectious Diseases, 53 papers in Epidemiology and 13 papers in Critical Care and Intensive Care Medicine. Recurrent topics in Robert Orenstein's work include Clostridium difficile and Clostridium perfringens research (40 papers), Microscopic Colitis (26 papers) and Nosocomial Infections in ICU (13 papers). Robert Orenstein is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (40 papers), Microscopic Colitis (26 papers) and Nosocomial Infections in ICU (13 papers). Robert Orenstein collaborates with scholars based in United States, Canada and France. Robert Orenstein's co-authors include Alan R. Zinsmeister, Sahil Khanna, Edward V. Loftus, William S. Harmsen, Laurence J. Egan, Jean–Frédéric Colombel, William J. Sandborn, Murat Törüner, Darrell S. Pardi and Patricia P. Kammer and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Robert Orenstein

94 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease

2008 770 citations William S. Harmsen, Robert Orenstein et al. profile →
The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study

2011 488 citations Sahil Khanna, Darrell S. Pardi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Orenstein United States	23	1.8k	1.8k	580	497	431	100	3.0k
Donna M. Ambrosino United States	26	1.8k 1.0×	2.5k 1.4×	194 0.3×	325 0.7×	83 0.2×	46	4.3k
Pier‐Angelo Tovo Italy	42	1.9k 1.0×	1.8k 1.0×	275 0.5×	253 0.5×	36 0.1×	190	5.0k
Kim Oren Gradel Denmark	25	718 0.4×	612 0.3×	258 0.4×	370 0.7×	42 0.1×	95	2.3k
Veli‐Jukka Anttila Finland	25	1.0k 0.6×	1.2k 0.7×	66 0.1×	295 0.6×	246 0.6×	88	2.1k
Peter Muir United Kingdom	29	1.1k 0.6×	726 0.4×	234 0.4×	259 0.5×	63 0.1×	97	2.3k
T. Christopher Mast United States	25	1.2k 0.6×	1.4k 0.8×	218 0.4×	308 0.6×	37 0.1×	57	2.6k
Elja Herva Finland	34	3.5k 2.0×	599 0.3×	311 0.5×	190 0.4×	58 0.1×	97	4.9k
Fausto de Lalla Italy	29	948 0.5×	853 0.5×	162 0.3×	599 1.2×	34 0.1×	85	2.4k
Brett Leav United States	19	880 0.5×	1.3k 0.8×	74 0.1×	184 0.4×	57 0.1×	36	2.0k
Kumar Visvanathan Australia	34	2.4k 1.3×	468 0.3×	200 0.3×	271 0.5×	29 0.1×	124	3.8k

Countries citing papers authored by Robert Orenstein

Since Specialization

Citations

This map shows the geographic impact of Robert Orenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Orenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Orenstein more than expected).

Fields of papers citing papers by Robert Orenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Orenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Orenstein. The network helps show where Robert Orenstein may publish in the future.

Co-authorship network of co-authors of Robert Orenstein

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Orenstein. A scholar is included among the top collaborators of Robert Orenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Orenstein. Robert Orenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allegretti, Jessica R., Paul Feuerstadt, W Knapple, et al.. (2025). Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflammatory Bowel Diseases. 31(8). 2112–2122. 1 indexed citations

Bacon, Andrew, et al.. (2025). 635: SEVERE HYPERAMMONEMIA SYNDROME DUE TO UREAPLASMA UREALYTICUM AND MYCOPLASMA HOMINIS INFECTION. Critical Care Medicine. 53(1).

Speiser, Lisa, Janis E. Blair, Ami A. Shah, et al.. (2023). A Case of Sustained Viral Shedding of Mpox With Ocular Involvement Resulting in Vision Loss. Open Forum Infectious Diseases. 11(1). ofad632–ofad632.

Lee, Christine, Thomas Louie, Adam Charles Harvey, et al.. (2023). Safety of fecal microbiota, live-jslm (REBYOTA^™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therapeutic Advances in Gastroenterology. 16. 1108357253–1108357253. 52 indexed citations

Nagarakanti, Sandhya & Robert Orenstein. (2023). Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?. Infection and Drug Resistance. Volume 16. 3137–3143. 10 indexed citations

Orenstein, Robert, Gail Hecht, Adam Harvey, Glenn S. Tillotson, & Sahil Khanna. (2023). Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections. Open Forum Infectious Diseases. 10(9). ofad456–ofad456. 3 indexed citations

Kasten, Mary J., Brian D. Lahr, Zachary A. Yetmar, et al.. (2023). COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients. Scientific Reports. 13(1). 21249–21249. 2 indexed citations

Ganesh, Ravindra, Colin Pawlowski, John C. O’Horo, et al.. (2021). Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. Journal of Clinical Investigation. 131(19). 36 indexed citations

Coffey, Jordan, Amy E. Glasgow, Kristina K. Pearson, et al.. (2021). Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19. npj Digital Medicine. 4(1). 123–123. 47 indexed citations

10.

Burger, Charles D., et al.. (2020). Research Response to SARS-CoV-2/COVID-19. Mayo Clinic Proceedings. 95(9). S52–S55. 4 indexed citations

11.

Patron, Roberto L., et al.. (2017). Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection. Clinical Infectious Diseases. 65(7). 1214–1217. 15 indexed citations

12.

Hálfdánarson, Þorvarður R., Holenarasipur R. Vikram, Shimon Kusne, et al.. (2016). Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature. Mycopathologia. 181(11-12). 787–798. 2 indexed citations

13.

Leekha, Surbhi, Brian D. Lahr, Rodney L. Thompson, et al.. (2016). Preoperative risk prediction of surgical site infection requiring hospitalization or reoperation in patients undergoing vascular surgery. Journal of Vascular Surgery. 64(1). 177–184. 8 indexed citations

14.

Orenstein, Robert, Erik R. Dubberke, Robert Hardi, et al.. (2015). Safety and Durability of RBX2660 (Microbiota Suspension) for RecurrentClostridium difficileInfection: Results of the PUNCH CD Study. Clinical Infectious Diseases. 62(5). 596–602. 161 indexed citations

15.

Campbell, Mark, Shimon Kusne, Kevin J. Renfree, et al.. (2015). Coccidioidal Tenosynovitis of the Hand and Wrist: Report of 9 Cases and Review of the Literature: Table 1.. Clinical Infectious Diseases. 61(10). 1514–1520. 10 indexed citations

16.

Jeraldo, Patricio, et al.. (2014). Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2(1). 10–10. 119 indexed citations

17.

Orenstein, Robert, et al.. (2011). A Targeted Strategy to Wipe Out Clostridium difficile. Infection Control and Hospital Epidemiology. 32(11). 1137–1139. 58 indexed citations

18.

Orenstein, Robert, Jon E. Rosenblatt, Lynne M. Sloan, et al.. (2009). High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity. Diagnostic Microbiology and Infectious Disease. 66(1). 24–28. 28 indexed citations

19.

Orenstein, Robert, et al.. (2002). Looking Beyond Highly Active Antiretroviral Therapy: Drug‐Related Hepatotoxicity in Patients with Human Immunodeficiency Virus Infection. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 22(11). 1468–1478. 12 indexed citations

20.

Orenstein, Robert, et al.. (1999). HIV treatment-associated hepatitis.. PubMed. 9(5). 339–46. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact